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Abstract Bacterial meningitis con- 
tinues to be a serious infectious dis- 
ease with a high morbidity and mor- 
tality in young children. Early recog- 
nition and initiation of adequate 
treatment are the major determinants 
for a good outcome. Recent advances 
in our understanding of the host 
inflammatory response by cytokines 
may result in the use of new thera- 
peutic strategies. Such modulation of 
the inflammatory response may re- 
duce the incidence of sequelae and 
death. The use of steroids as adjunc- 
tive therapy in children with bacte- 
rial meningitis probably has benefi- 
cial effects although the available 
data are still controversial. Addition- 
ally, studies in experimental menin- 
gitis models indicate that non-stero- 
idal anti-inflammatory drugs and 
monoclonal antibodies against bacte- 
rial products, cytokines and CD18 on 
leucocytes reduce the extent of the 
meningeal inflammation. Human 
studies to evaluate the efficacy of 
these immune modulators are ex- 
pected to start soon. However, pre- 
vention of bacterial meningitis by 
conjugate vaccines against Strepto- 
coccus pneumoniae and Neisseria 
meningitidis will be the most promis- 
ing development in the next decade. 
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Abbreviations ADH antidiuretic 
hormone 9 BBB blood brain barrier 
Hib Haemophilus influenzae type b 
IFN interferon 9IL interleukin 9 LPS 
lipopolysaccharide 9 PAF platelet 
activating factor 9 PGE2 prostaglandin 
E2 9 PMN polymorphonuclear 
leucocyte 9SIADH syndrome 
of inappropriate secretion of 
antidiuretic hormone 9 TNF tumour 
necrosis factor 
Introduction 
Despite continuing improvements in therapy bacterial 
meningitis is still associated with fatality rates of 3%-6% 
and the development of severe sequelae in approximately 
16% of cases [6, 33, 86, 101, 115, 116]. Prevention of 
meningitis by the use of novel conjugate vaccines against 
Streptococcus pneumoniae and Neisseria meningitidis 
will be a point of major interest in the next decade. Recent 
research has contributed to our understanding of the 
pathophysiology of bacterial meningitis. This has resulted 
in new therapeutic approaches. The use of anti-inflamma- 
tory drugs in combination with antibiotics in bacterial 
meningitis has become a topic of major interest. This re- 
view will focus on the nature of the inflammatory re- 
sponse to infection in the CSF and the pathophysiological 
alterations induced by bacterial meningitis. Finally, recent 
advances in treatment will be discussed. 
Epidemiology 
Bacterial meningitis is mainly a disease of young chil- 
dren. During the neonatal period Gram-negative enteric 
bacilli (Escherichia coli, Klebsiella species), group B 
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Fig. 1 Schematic view of the 
biochemical changes in the 
CSF profile and detection of 
elevated cytokine levels during 
bacterial meningitis. The nor- 
mal ranges (N) for white blood 
cells (WBC), protein, glucose 
and lactate in the CSF are indi- 
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tion of antibiotic therapy 
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streptococci and Listeria monocytogenes are the most 
common pathogens. These organisms are mainly acquired 
at delivery. The three major causative organisms in infants 
above 3 months of age are N. meningitidis, Haemophilus 
influenzae and S. pneumoniae. They account for more 
than 90% of bacterial meningitis in children between 3 
months and 10 years. The incidence and relative frequen- 
cies of these bacteria differ markedly depending on ge- 
netic factors, the geographic area and the recent introduc- 
tion of the efficacious conjugate H. influenzae type b vac- 
cine in many countries. 
Epidemiological studies have identified several risk 
factors for bacterial meningitis. Age is the most important 
risk factor. Boys are affected more frequently than girls. 
Several studies have reported the presence of racial differ- 
ences in the incidence of bacterial meningitis. Black and 
Hispanic populations are at 2-4 times greater isk than 
Caucasians [26, 31, 35, 130]. Socioeconomic rather than 
racially determined factors are responsible for the in- 
creased risk [31]. The native North American population 
also has a high incidence of bacterial meningitis. For ex- 
ample, rates of over 200/100000 per year in the overall 
population have been described among Canadian Inuits 
[132]. Another host factor which increases the risk of 
pneumococcal sepsis and meningitis is splenectomy. Pa- 
tients with deficiencies in the terminal components of 
complement (C5-9) also have a high risk of meningococ- 
cal meningitis. Children in day care centres have an in- 
creased risk of acquiring invasive bacterial disease in 
comparison with children in home care. 
Diagnosis of bacterial meningitis 
Nonspecific linical findings predominate in the newborn 
and in young infants. These include abnormal tempera- 
ture, somnolence, irritability, and poor feeding. The pres- 
ence of a bulging fontanelle is a relatively characteristic 
sign in this age group but not present early in the disease. 
More characteristic findings are often seen in children and 
adults and include alteration of the mental status, nuchal 
rigidity, and the signs of Kernig and Brudzinski. A lumbar 
puncture has to be performed if the slightest evidence sug- 
gests the presence of bacterial meningitis. Rapid diagno- 
sis and initiation of therapy are the major prognostic fac- 
tors determining a favourable outcome. Initial manage- 
ment decisions are based largely on the Gram stain and 
CSF characteristics (leucocytes, glucose, lactate and pro- 
tein). The cS  F parameters eflect he metabolic and struc- 
tural alterations, such as increased blood brain barrier 
(BBB) permeability, which characterize the inflammatory 
response (Fig. 1). 
Leucocytes 
A characteristic feature of meningitis is CSF leucocytosis. 
Before leucocytes reach the CSF a co-ordinated action 
takes place of adherence to vascular endothelium, dia- 
pedesis out of the bloodstream and subsequent migration 
across the endothelial monolayer into the CSF compart- 
ment. This process is mediated by adhesion=promoting re- 
ceptors and ligands located on leucocytes and endothe- 
lium which are activated by exposure to cytokines (inter- 
leukin (IL)-I ~, tumour necrosis factor (TNF) o~ and inter- 
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feron (IFN) T) and lipopolysaccharide (LPS) [62, 68, 84, 
85, 93]. Bacterial replication or lysis in the CSF compart- 
ment induces endothelial cells to produce IL-8. IL-8 is a 
potent chemoattractant [5]. The initial reversible adher- 
ence of leucocytes to endothelial cells is mediated by 
three lectin-like carbohydrate-binding molecules called 
selectins (granule membrane protein-140, endothelial cell 
adhesion molecule-I, leucocyte adhesion molecule-l). 
Each selectin recognises pecific carbohydrate s quences 
on either leucocytes (granule membrane protein-140, en- 
dothelial cell adhesion molecule-i) or endothelial cells 
(leucocyte adhesion molecule-I). Strong adhesion is me- 
diated by leucocyte integrins that bind to counter ecep- 
tors on endothelium. The integrin family of adhesion re- 
ceptors (CDll/CD18) consist of heterodimeric glycopro- 
teins with an c~ and [~ subunit. They can be classified on 
basis of their ~ subunit [46]. The early selectin-adhesion 
decreases with continued cytokine stimulation by cleav- 
age of the selectin of the cell surface or inhibition of its 
binding. At the same time ~3 z integrin-mediated a herence 
of the neutrophils to intercellular adhesion molecule-1 
(ligand) on endothelial cells is induced. Subsequently leu- 
cocytes traverse the cerebral capillary endothelium by di- 
apedesis [103]. 
Glucose and lactate 
The changes in glucose and lactate levels are not only in- 
duced by living bacteria and leucocytes. The anaerobic 
brain metabolism in bacterial meningitis contributes to 
the development of increased CSF lactate concentration 
and hypoglycorrhachia [123]. It seems likely that local 
changes in the brain as a result of ischaemia or mediated 
by humoral factors, induce an increased production of lac- 
tate. Another explanation for the development of hypo- 
glycorrhachia was demonstrated in experimental canine 
meningitis. In these animals low CSF glucose reflected 
the inhibition of carrier-mediated transport across the 
BBB [21, 88]. The increased use of glucose by the brain 
and the abnormal glucose transport across the BBB may 
further contribute to hypoglycorrhachia [43]. 
Protein 
The elevated concentration of protein in CSF during bac- 
terial meningitis is caused by an increased permeability of 
the BBB. A uniform response consisting of an early and 
sustained increase in formation of pinocytotic vesicles 
and a progressive increase in the separation of tight junc- 
tions between endothelial cells is observed during the 
course of experimental meningitis [99]. The cytokine-en- 
dothelium-leucocyte interaction is probably responsible 
for the disruption of the barrier by opening intercellular 
junctions and permitting the passage of serum proteins 
into the subarachnoidal space. 
Pathogenesis of infection 
The three most common micro-organisms in bacterial 
meningitis have several properties that promote adher- 
ence, colonization and invasion of the mucous mem- 
branes of the nasopharynx. Mucosal attachment is medi- 
ated by microbial virulence factors such as pili and non- 
pilar adhesins. Several host defence mechanisms must be 
evaded before attachment may occur. The bacteria have to 
inactivate secretory IgA and escape from the ciliary clear- 
ance mechanisms of the nasopharyngeal mucosa. The 
three major pathogens all secrete a protease capable of 
cleaving human immunoglobulin A1. Importantly, IgA1 
is the dominant immunoglobulin class in the nasopharyn- 
geal mucosa which is the site of adherence and invasion 
by these bacteria [24, 83]. 
Invasion across the nasopharyngeal mucosa takes 
place by an endocytotic process (N. meningitidis) or 
through the intercellular route by separations in the apical 
tight junctions of columnar epithelial cells (H. influenzae) 
[106, 107]. Once the mucosal barrier is crossed, bacteria 
must overcome additional host defences to survive in the 
bloodstream and to invade the meninges. The most im- 
portant virulence factor in this respect is encapsulation. 
The polysaccharide capsule inhibits neutrophil phagocy- 
tosis and prevents classical complement pathway bacteri- 
cidal activity thus enhancing intravascular bacterial repli- 
cation and survival. 
Pathophysiology of the inflammatory response 
Since CSF defences against infection are very limited 
bacteria can proliferate rapidly. Host defence (humoral 
factors and phagocytes) must be recruited from serum, a 
process that develops parallel to blood brain barrier dis- 
mption and alteration of the cerebral metabolism. These 
abnormalities all arise as part of an inflammatory re- 
sponse mediated by cytokines. 
Cell-wall components 
Experimental evidence has accumulated that cell-wall 
components are responsible for triggering the inflamma- 
tory response in the subarachnoid space. These are mainly 
peptidoglycan-teichoic acid in Gram-positive micro-or- 
ganisms and LPS molecules (endotoxins) in Gram-nega- 
tive bacteria. Both are potent inducers of inflammation. 
Intracisternal inoculation of any of these components into 
the CSF compartment of animals induces meningeal in- 
flammation [110, 117, 118, 131]. Observations in animals 
with experimental pneumococcal swell as H. influenzae 
meningitis indicate that initiation of antibiotic therapy re- 
sults in a more pronounced increase in inflammatory in- 
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dices and cytokine levels in the CSF [71,112, 119]. Addi- 
tional evidence indicates that LPS does not act alone dur- 
ing Gram-negative bacillary meningitis [11]. These bacte- 
ria also contain similar amounts of peptidoglycan [48]. 
LPS is not present in the CSF in sufficiently high concen- 
trations to directly injure the cerebrovascular endothe- 
lium. In contrast, clinically relevant concentrations of 
LPS (1-10 ng/ml) are able to induce CSF leucocytosis 
and are potent at priming leucocytes for the production of 
inflammatory mediators. Peptidoglycan is only a weak in- 
ducer of inflammatory mediators. However, peptidogly- 
can can cause cellular separation of endothelia t concen- 
trations 100-fold less than required for LPS and may be 
responsible for the induction of BBB permeability in 
Gram-negative meningitis [74]. 
Two studies in infants with Gram-negative meningitis 
have demonstrated increased endotoxin concentrations in 
CSF and ventricular fluid when intrathecal or intraventric- 
ular antibiotic therapy was given in addition to parenteral 
antibiotics. This increased endotoxin concentrations have 
been associated with an augmented meningeal inflamma- 
tion and with a rise in adverse outcome in infants with co- 
liform meningitis treated with intraventricular gentamicin 
[3, 65, 66, 70]. 
Cytokines 
The host responds with the release of cytokines upon 
recognition of the presence of bacterial products in the 
subarachnoidal space. TNF(~ and IL-113 appear to play a 
pivotal role in triggering the cascade of meningeal inflam- 
mation [91]. I1-6, another cytokine found in CSF from pa- 
tients with bacterial meningitis, has also been implicated 
in the pathogenesis of this infection. Although production 
of these inflammatory c tokines has been linked to the de- 
velopment of CNS injury, the precise mechanism has not 
been elucidated. It has been suggested that cytokines are 
produced by glial cells and brain capillary endothelial 
cells [67]. Experimental studies have indicated that in- 
tracisternal inoculation of endotoxin is followed by detec- 
tion of TNFo~ and IL- 1 I] activity. Subsequently, leucocyto- 
sis and changes in protein, glucose and lactate concentra- 
tions are observed within hours. Combined injection of 
TNFc~ and IL-113 into the CSF has a synergistic effect 
[119]. Administration of dexamethasone or polymyxin b
before or together with H. influenzae type b (Hib) lipo- 
oligosaccharide, inhibits CSF TNFc~ and decreases the 
meningeal inflammatory response [51, 71, 72, 109]. 
TNFo~ and IL-1 [3 can also be detected in initial CSF sam- 
ples of children with bacterial meningitis [126]. The pres- 
ence of IL-113 is associated with CSF inflammatory abnor- 
malities, TNFc~ concentration and an adverse outcome 
[69]. Some reports describe an association between in- 
dices of inflammation or the clinical course and TNFo~, 
IL-I[3 and IL-6 levels. Infants with culture-proven viral 
meningitis or with non-infected CSF have low or non- 
detectable IL-11] and TNFc~ levels [18, 39, 59, 61, 77, 90]. 
Arachidonic acid metabolites 
Arachidonic acid metabolites play an important role as 
mediators and/or modulators of inflammation. These 
products may be involved in many of the pathological 
processes in meningitis. They are released after stimula- 
tion with bacterial and immunological ntigens by a vari- 
ety of cells, including neutrophils, platelets, and vascular 
endothelial cells. TNFc~ and IL-I~ induce phospholipase 
A2 activity thereby triggering the production of these pro- 
inflammatory substances [64]. 
Previous studies have demonstrated a significant in- 
crease in prostaglandin E2(PGE2) (cyclo-ogygenase prod- 
ucts) but not leukotriene B 4 (lipo-oxgygenase product) 
concentration i  CSF during pneumococcal meningitis in 
rabbits [49]. Intracisternally administered PGE 2 did not 
induce detectable CSF leucocytosis, but caused a dose-re- 
lated increase in protein content [50]. PGE2 and PGI2 are 
elevated in the CSF of infants and children with bacterial 
meningitis. The concentration of PGE 2 correlates ignifi- 
cantly with protein, TNFo~, and IL-113 concentrations in 
the initial CSF sample [73]. 
PAF 
CSF platelet activating factor (PAF) concentrations are 
significantly higher in children with H. influenzae menin- 
gitis than in afebrile and febrile control subjects without 
meningitis. The concentrations correlate strongly with 
concomitant bacterial counts and with both LPS and 
TNFct concentrations in admission CSF samples. LPS and 
a variety of cytokines, such as TNF~ and IL-I~3, are po- 
tent inducers of PAF by polymorphonuclear leucocytes 
(PMN), macrophages/monocytes, endothelial cells and 
neuronal cells [8, 82, 125]. PAF recruits and activates 
PMNs and monocytes at the site of inflammation and in- 
duces the release of other inflammatory mediators. PAF in 
high concentrations is toxic to neuronal cells. PAF acts 
synergistically with LPS and TNF~ in the development of
microvascular tissue damage [4, 12]. 
Leucocytes 
Several hours after meningeal infection an intense influx 
of leucocytes occurs. Cytokines timulate the function of 
neutrophils and provoke degranulation superoxide pro- 
duction and increased adherence to the endothelium. It
has been demonstrated that products of leucocytes, uch 
as polyunsaturated fatty acids and oxygen-free radicals 
can induce brain oedema, increased lactate production, 
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and energy depletion in cortical brain slices of rats [16, 
28]. However, not all studies demonstrate adverse ffects 
of leucocytes. When the effects of experimental pneumo- 
coccal meningitis were compared between normal and 
neutropenic rabbits similar changes of brain water content 
(brain oedema), intracranial pressure, and CSF concentra- 
tion of lactate and protein were observed [113]. 
Therapy 
Antimicrobial therapy 
The combination of ampicillin and chloramphenicol has 
been known for many years as an effective mpirical ther- 
apy of bacterial meningitis. Ampicillin resistant [3-1acta- 
mase producing H. influenzae has become a major prob- 
lem in many European countries and the United States of 
America. A recent collaborative European study shows a 
mean rate of resistance of 10% for all participating coun- 
tries [63]. In addition, sporadic ases of chloramphenicol- 
resistant H. influenzae have been documented. Combined 
resistance to chloramphenicol and beta-lactams is increas- 
ing [13, 14, 36, 42, 102, 124]. IV. meningitidis resistant 
to ~-lactam antibiotics is also increasingly encountered. 
Spain has been a major source for penicillin-resistant N. 
meningitidis [96]. Infections caused by resistant patho- 
gens lead to higher rates of morbidity and mortality than 
infections caused by susceptible pathogens. 
A consensus among experts about he choice of initial 
empiric therapy of childhood meningitis is still lacking. 
Third generation cephalosporins have become important 
antibiotics for the treatment of presumed bacterial menin- 
gitis in infants and children [19, 56, 75, 104]. Among 
these cephalosporins, cefotaxime, ceftriaxone, and cef- 
tazidime have been studied extensively [32, 44, 92]. All 
three agents are extremely active against H. influenzae 
(including 13-1actamase producing strains), N. meningitidis 
and S. pneumoniae. However, cephalosporins are inactive 
against Listeria monocytogenes, Streptococcus faecalis 
and methicillin-resistant staphylococci. Empiric therapy 
of bacterial meningitis in children up to 3 months of age 
should include ampicillin for activity against L. monocy- 
togenes and enterococci. Once the aetiological agent has 
been identified and its susceptibility determined, therapy 
can be altered to a single drug or a combination of drugs 
active in vitro. The duration of therapy is dependent on 
the clinical response of the patients. Seven days is gener- 
ally considered adequate for meningococcal infections 
and 10 days for H. influenzae and pneumococcal menin- 
gitis [89]. Despite the availability of active antibiotics 
against he common meningeal pathogens the outcome of 
meningitis has not changed over the last decades. There- 
fore investigators have been focusing on novel ap- 
proaches to diminish neurological sequelae of menin- 
gitis. 
Fluid restriction 
It is generally recommended that children with bacterial 
meningitis receive less than maintenance fluid to treat or 
prevent the syndrome of inappropriate s cretion of antidi- 
uretic hormone (SIADH) [25, 52]. However, a recent 
study in infants with bacterial meningitis hows that ele- 
vated levels of antidiuretic hormone (ADH) may also be 
explained as an appropriate r sponse to intravascular vol- 
ume depletion rather than as the result of hypothalamic- 
pituitary axis dysfunction [87]. The loss of cerebrovascu- 
lar autoregulation in bacterial meningitis may be compen- 
sated by secretion of ADH to maintain adequate cerebral 
blood flow. The cerebral blood flow during bacterial 
meningitis depends on the cerebral perfusion pressure 
which is the difference between the mean arterial blood 
pressure and the intracranial pressure. Two studies in rab- 
bits with experimental meningitis compared fluid restric- 
tion with a normal fluid regimen. Fluid restriction resulted 
in reduced mean arterial blood pressure, significantly de- 
creased cerebral blood flow and increased anaerobic gly- 
colysis of the brain. The fluid regimen, however, did not 
have a major effect on the degree of brain oedema [114, 
123]. Since cerebral blood flow is often reduced in bacte- 
rial meningitis, fluid restriction may even worsen the neu- 
rological outcome. Clinical trials to evaluate the effect of 
fluid regimen on outcome have not been performed. Cur- 
rent recommendation in children with bacterial meningitis 
may have to be revised in view of these new experimental 
data. Fluid restriction should possibly only be limited to 
those patients with meningitis who fulfil the diagnostic 
criteria for SIADH. 
Adjunctive therapy 
The improvements in our understanding of the pathophys- 
iology of bacterial meningitis may lead to the develop- 
ment of novel therapeutic approaches. Modulation of the 
inflammatory cascade may reduce the incidence of seque- 
lae and death in patients with bacterial meningitis. Inter- 
ventions will be directed against harmful bacterial prod- 
ucts (e.g. monoclonal antibodies, polymyxin B), cyto- 
kines (e.g. monoclonal antibodies, steroids), leucocytes 
(e.g. monoclonal ntibodies, pentoxiphylline, radical scav- 
engers) or some consequences of the disease, e.g. brain 
oedema, increased intracranial pressure or alterations of 
the cerebral blood flow (Table 1). 
Corticosteroids 
In vitro studies indicate that pretreatment of cultured cells 
with dexamethasone suppresses the synthesis and release 
of cytokines induced by bacterial products [9, 54, 58]. 
The inflammatory esponse in the CSF of rabbits after in- 
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Table 1 Adjunctive anti-inflammatory agents in the treatment of 
bacterial meningitis 
- Corticosteriods 
- Monoclonal antibodies 
9 Anti-endotoxin 
9 Anti-IL-1[3; anti-TNFc~ 
9 Anti-CD18 
- Cyclo-oxygenase inhibitors 
- Pentoxifylline 
- Radical scavengers 
9 Superoxide dismutase 
9 Catalase 
tracisternal inoculation of  bacterial products uch as endo- 
toxin or live H. influenzae may be blocked by dexametha- 
sone. However, this is only effective when dexametha- 
sone is initiated before or at the same time as the antibi- 
otic [51, 71, 72]. TNFa  and IL-I[3 levels in the CSF are 
reduced concomitmltly with concentrations of PGE2 [73]. 
Dexamethasone also decreases brain water content, in- 
tracranial pressure, and CSF lactate in animals with S. 
pneumoniae or H. influenzae meningitis [100, 109, 111]. 
Clinical studies to evaluate the efficacy of  dexametha- 
sone in bacterial meningitis have yielded controversial re- 
sults (Table 2). Lebel et al. [57] demonstrated that con- 
ventional antibiotic therapy (cefuroxim or ceftriaxone) 
plus dexamethasone r sulted in improved outcome in the 
treatment group in comparison with a placebo-treated 
group. Children treated with dexamethasone had a signif- 
icantly lower incidence of sensorineural deafness (15% vs 
3.3%) and of other neurological sequelae 12 months later 
[57]. The study of Odio et al., in which dexamethasone 
administration was started before the initiation of cefo- 
taxime therapy failed to find a significant reduction in 
hearing impairment in the steroid treated group. However, 
an overall reduction in the incidence of neurological com- 
plications (including hearing loss) was seen in the treat- 
ment group in comparison with a placebo group (14% vs 
38%) [76]. The majority of cases of meningitis in these 
two studies were due to H. influenzae while N. meningi- 
tidis and S. pneumoniae will become more important in 
the coming years due to the introduction of Haemophilus 
conjugate vaccines. In a study from Egypt mortality was 
reduced in patients (children and adults) with pneumococ- 
cal meningitis by using dexamethasone. This cortico- 
steroid also protected against hearing loss in this group of 
patients [38]. These three studies showed a significant re- 
duction in neurological sequelae with dexamethasone, but 
benefits were statistically significant only when the se- 
quelae were unusually common as result of  suboptimal 
therapy (cefuroxim), supportive, and diagnostic manage- 
ment (in developing countries). The results of  these stud- 
ies could not be confirmed in more recent rials, which de- 
Table 2 Overview of sequelae 
in recent placebo/dexametha- 
sone therapy studies in chil- 
dren treated for bacterial 
meningitis (SEQ sequelae, 
NA not available, NS not sig- 
nificant) 
Study Antibiotic 
therapy 
Lebel et al. [57] Cefuroxim 
Lebel et al. [57] Ceftriaxone 
Odio et al. [76] Cefotaxime 
King et al. [55] Not uniform 
Wald et al. [127] Ceftriaxone 
Schaad et al. [98] Cefu'iaxone 
Schaad et al. [98] Ceftriaxone 
(meta-analysis) 
No (%) of children with audiological (A), 
neurological (N) or combined (C) sequelae 
SEQ Placebo Dexamethasone 
P 
A 16/ 38 (42) 9/ 43 (21) < 0.05 
N 3/ 34 (9) 1/ 38 (3) NS 
C NA NA NA 
A 14/ 46 (30) 7/ 49 (14) NS 
N 6/ 41 (15) 2/ 43 (5) NS 
C NA NA NA 
A 7/ 44 (16) 5/ 50 (6) NS 
N 15/ 48 (31) 5/ 51 (10) 0.008 
C 18/ 48 (38) 7/ 51 (14) 0.007 
A 4/ 51 (9) 5/ 48 (11) NS 
N 3/ 51 (7) 3/ 48 (6) NS 
C NA NA NA 
A NA NA NA 
N NA NA NA 
C 10/ 74 (14) 6/ 68 (9) NS 
A 8/ 55 (15) 3/ 60 (5) NS 
N 5/ 55 (9) 3/ 60 (5) NS 
C 9/ 55 (16) 3/ 60 (5) NS 
C 28/175 (16) 12/177 (7) 0.007 
91 
tected no significant difference between steroid-treated 
patients and control subjects [55, 98, 127]. However, a 
meta-analysis of sequelae in ceftriaxone-treated bacterial 
meningitis in children indicated that dexamethasone as 
adjuvans therapy is superior to placebo [98]. The Ameri- 
can Academy of Pediatrics advises to use dexamethasone 
in patients with proven or strongly suspected bacterial 
meningitis. However, the Canadian Pediatric Society has 
not yet decided to recommend routine use of dexametha- 
sone therapy [2, 47]. 
Furthermore, the use of corticosteroids is associated 
with potential side-effects supporting the need for more 
information to assess the risks or benefits [45]. In the re- 
port by Lebel et al. [57], 2% of the patients bad gastro-in- 
testinal bleeding. None of the patients receiving placebo 
had this complication. At present, he frequency and sever- 
ity of this complication of dexamethasone ar unknown. 
Other studies indicate that glucocorticoids potentiate isch- 
aemic injury to neurons. Since decreased cerebral blood 
flow appears to be one of the pathophysiological features 
of bacterial meningitis, it is important to know whether 
dexamethasone has beneficial effects on hearing but 
worsens cerebral cortical function [97]. These important 
questions concerning the place of corticosteroids should 
be addressed further in carefully conducted clinical trials 
in homogeneous populations. 
Monoclonal antibodies against endotoxin 
Inhibition of the effects of endotoxin may have beneficial 
effects on Gram-negative bacterial meningitis ince the 
toxic moiety of endotoxins, lipid A, can be neutralized by 
polymyxin B or by a monoclonal ntibody to lipid A [7, 
128, 133, 134]. Indeed, cures of bacterial meningitis were 
achieved in the pre-antibiotic era by direct installation of 
immune serum supplemented with complement [1, 27, 29, 
30]. Direct CSF inoculation was needed for this therapy. 
Experimental studies in rats demonstrate that intravenous 
administration f an IgG monoclonal antibody results in 
low CSF levels (< 5.5%) [37]. Intracisternal inoculation 
of an IgM monoclonal ntibody or polymyxin b directed 
against the lipid A moiety of E. coli LPS reduced the ce- 
fotaxim-induced increase in CSF LPS concentration a d 
brain water content. The monoclonal ntibody was clearly 
more effective in reducing brain water content although 
no differences were observed in the capacity to neutralize 
endotoxin [112]. 
Monoclonal antibodies against cytokines 
Intracisternal dministration f TNFc~ and IL-1 ~ in rabbits 
induces a brisk inflammatory response which may be 
blocked by antibodies against he cytokines. Moreover, 
simultaneous intracisternal dministration f anti-TNF(x 
polyclonal antibody with Hib lipooligosaccharides neutral- 
izes CSF TNFo~ activity and is associated with substantial 
attenuation f the meningeal inflammatory changes [72]. 
Monoclonal antibodies against CD18 
Agents that attenuate the augmented granulocyte-en- 
dothelial interaction followed by leucocyte influx into 
CSF could be beneficial in preventing brain damage. 
Monoclonal antibodies against the CD18 family of adhe- 
sion-promoting receptors on leucocytes have been stud- 
ied. Animals receiving intravenous mAb IB4 (anti-CD18) 
before intracisternal inoculation with living bacteria (S. 
pneumoniae, H. influenzae, N. meningitidis), endotoxin or 
cell-wall demonstrate a dramatic reduction in CSF leuco- 
cyte density and protein concentration. Cerebral oedema 
was absent in mAb-treated animals [95, 120]. 
Inhibition of prostaglandins 
Non-steroidal nti-inflammatory agents inhibit the cyclo- 
oxygenase pathway and reduce meningeal inflammation 
in bacterial meningitis. Cyclo-oxygenase inhibitors (in- 
domethacin, diclofenac, oxindanac) block the develop- 
ment of brain oedema nd decrease the number of leuco- 
cytes in comparison with non-treated animals. In addition, 
the influx of protein in the CSF compartment is prevented 
by these inhibitors. Oxindanac has a stronger activity than 
other cyclo-oxygenase inhibitors (indomethacin, diclofe- 
nac). A study in rabbits with experimental meningitis dem- 
onstrated a dramatically decreased mortality by the use of 
a combination ofampicillin plus oxindanac in comparison 
with treatment with ampicillin alone or ampicillin plus 
dexamethasone or indomethacin. Trials of selected non- 
steroidal anti-inflammatory agents hold much promise 
[49, 50, 119, 121,122]. 
Pentoxifylline 
Recent studies uggest that pentoxifylline, a xanthine-de- 
rived phosphodiesterase inhibitor, can inhibit the inflam- 
matory process. Pentoxifylline can reverse or counteract 
many of the effects of endotoxin and endotoxin-induced 
cytokines on leucocyte function [108]. Studies in rabbits 
with experimental meningitis indicate that continuous in- 
travenous infusion of pentoxifylline compared with saline 
significantly reduces CSF concentrations of leucocytes, 
protein, and lactate [94]. Pentoxifylline also reduces the 
release of cytokines from primary murine microglial cell 
cultures. When added concomitantly with LPS, pentoxi- 
fylline blocked the release of TNFc~ and IL-I~ but not 
IL-6, while dexamethasone i hibited the release of TNFor 
and IL-6. Pentoxifylline, but not dexamethasone, inhib- 
ited TNFcr release from microglia previously stimulated 
with LPS [17]. 
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Radical scavengers: uperoxide dismutase and catalase 
Reactive oxygen species in experimental meningitis are 
capable of inducing vasodilation of cerebral arterioles, in- 
creased BBB permeability, increased lactate production 
and brain oedema. Pfister et al. studied the effects of two 
radical scavengers in experimental meningitis. Superox- 
ide dismutase completely blocked the increase of regional 
blood flow, intracranial pressure, and brain water content 
during the early phase of experimental pneumococcal 
meningitis. Catalase, another radical scavenger, only partly 
attenuated the increase of regional cerebral blood flow, in- 
tracranial pressure and brain water content. These results 
suggest hat the increase of regional cerebral blood flow, 
brain water content, and intracranial pressure is mainly 
caused by superoxide or its products [80, 81]. 
Vaccination 
Recently, conjugate vaccines against Hib have been de- 
veloped. These vaccines, but not the previous non-conju- 
gated ones, are immunogenic and effective during the age 
of the highest incidence of meningitis caused by Hib. A 
very low rate of side-effects was noted [20, 22, 23, 40, 
41, 53, 78, 129]. Hence, Hib vaccination has been intro- 
duced in childhood vaccination programmes in an in- 
creasing number of countries. Subsequently a 90% reduc- 
tion in H. influenzae meningitis has been observed [23, 
79]. However, a substantial number of children have bac- 
terial meningitis caused by N. meningitidis and S. pneu- 
moniae. Meningococcal disease is caused by several 
serogroups N. meningitidis; serogroup B is the most com- 
mon cause in Europe, North-America nd several coun- 
tries in Latin America. A meningococcal non-conjugate 
tetravalent A, C, Y, and W135 polysaccharide vaccine is 
available and has been shown to be safe and immunogenic 
in adults, but not in young infants. The serogroup B poly- 
saccharide, however, is poorly immunogenic in humans 
and has not been useful for development of a vaccine. 
Therefore, vaccines based on outer membrane proteins are 
currently being evaluated for their efficacy [34, 60]. Re- 
cent field trials with such vaccines have demonstrated only 
partial protection against group B infection [10, 15]. Sev- 
eral pneumococcal conjugate vaccines combining the most 
relevant serotypes coupled to different protein antigens 
are already available [105]. 
The final aim would be a combined conjugate vaccine, 
including adequate immunogenic structures of Hib, me- 
ningococci and pneumococci to provide a protective anti- 
body response at an early age. 
Conclusions 
Brain damage in patients with bacterial meningitis results 
from the combined eleterious effects of the micro-organ- 
isms and its products and of the host inflammatory re- 
sponse. A number of pathophysiological alterations have 
been demonstrated in animal models. These include brain 
oedema, elevation of intracranial pressure, changes in 
CSF outflow resistance, morphological changes of the 
BBB, and changes in cerebral blood flow. In addition, me- 
diators of pathophysiological changes have been identi- 
fied, including cytokines, cyclo-oxygenase m tabolites, and 
PAE Several adjunctive therapeutic interventions have 
been developed to modulate the damaging host response 
to invading micro-organisms. The new treatment strate- 
gies are directed against bacterial products, cytokines and 
white blood cells. Most of these adjunctive therapies have 
only shown advantageous effects when administered be- 
fore or simultaneously with the induction of experimental 
meningitis. However, pentoxifylline has been shown to at- 
tenuate the inflammatory process by reducing the release 
of cytokines in a model previously exposed to endotoxin. 
The use of corticosteroids a  adjunctive treatment in hu- 
man studies shows the presence of a possible beneficial 
effect. Nevertheless, routine use of steroids in children with 
bacterial meningitis is still a subject of intense debate be- 
cause recent studies did not demonstrate a significant dif- 
ference in the percentage of nettrological or audiological 
sequelae. Although improvement of treatment s rategies has 
given encouraging results, prevention of bacterial menin- 
gitis by development and introduction of a combined con- 
jugate vaccine against he three common causative patho- 
gens will be the major challenge of the next decade. 
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